Home › Orexigen Therapeutics resubmits Contrave to FDA
 

Keywords :   


Orexigen Therapeutics resubmits Contrave to FDA

2013-12-12 11:39:48| Biotech - Topix.net

The FDA refused to approve Contrave in 2011, citing concerns over cardiovascular risk.

Tags: fda therapeutics

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.11Registration Now Open for RadTech 2025
05.11Atlantic Tropical Weather Outlook
05.11Eastern North Pacific Tropical Weather Outlook
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Public Advisory Number 7A
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Vodafone-Three merger could get green light, watchdog says
05.11Altice USA residential video RGUs down 77,000 in 3Q 2024
More »